In the previous published academic journal literature, Alchangkang ® double-target fecal DNA detection products have been verified by a number of testing units, including Peking Union Medical College Hospital, Zhongnan Hospital of Wuhan University, the First Affiliated Hospital of Anhui Medical University, etc. The excellent performance of Alchangkang ® products has been fully confirmed and the mechanism of double-target detection to improve detection sensitivity has been initially explained. The research was published in Frontier MolecularBioscience and The Journal of Molecular Diagnostics.
↓：
· Get the authoritative certification again! | Alchangkang@multi-center clinical research results were published again in authoritative international journals (impact factor 5.568)
-
Test method
In this study, the researchers first divided colorectal cancer samples into three groups based on the promoter methylation status of SDC2 and TFPI2: SDC2/TFPI2 double positive group (group HH), SDC2/TFPI2 single positive group (group HL), and SDC2/TFPI2 double negative group (group LL). Clinicopathological parameters and molecular characteristics were evaluated by internal and external cohorts, including the TCGA, GEO and D311 bowel cancer datasets.
The researchers first compared the relationship between the three groups of samples and colorectal tumor sites. Across all datasets, there was no preference for the distribution of HH and LL in different tumor locations, while HL samples were mainly from the left colon and only a small number from the right colon and rectum.
The study demonstrated that the HH group (i.e., both SDC2 and TFPI2 methylation positive) had the highest microsatellite instability and mutation load compared to the other two groups.
Patient age is a risk factor for colon cancer,
The findings suggest thatIn particular, detection of colorectal cancer with single target methylation alone may result in higher missed detection. Given that left-sided colorectal cancer is more prevalent in the East Asian population, the different characteristics of this single methylated tumor marker in the left and right colon may increase the risk of missed colorectal tumors, and healthcare professionals need to evaluate the influence of multiple factors, including anatomical location, in the clinical use of methylation testing.
Cancer early screening, beat cancer